Hungary Egis inaugurates new EUR 15.2 m R&D facility, inks strategic deal with gov’t

“In order to enhance the competitiveness and the performance of the Hungarian economy the Government concludes strategic cooperation agreements with companies contributing outstandingly to the Hungarian economy. Taking into account the Government's efforts and the important role of Egis in the Hungarian economy, a strategic cooperation agreement was signed today between the Government and Egis," the company said in a statement today.

Pursuant to the agreement the cabinet is “ready to encourage innovation and R&D activities of Egis in Hungary with the available means."

Egis’ R&D strategy focuses on development areas applying latest technologies, which allow the company to conquer new drug-market segments as well as to increase competitiveness.

In addition, the agreement also addresses the strengthening and the promotion of exports of own products manufactured in the plants of Egis located in Hungary.

New API R&D plant inaguruated

The new API (active pharmaceutical ingredient) Research and Development Centre was established with an investment of HUF 4.6 billion and co-funded by the EU and the Hungarian state with an amount of HUF 1,149 billion.

“This plant enables Egis to develop cutting-edge, so called high-potency active ingredients. These active ingredients have significant biological effects even in small quantities and provide advanced therapies especially in the field of oncology. The labs were designed by taking special engineering, HVAC (heating, ventilation and air conditioning) and automation viewpoints into account," Egis said.

Egis’ new API R&D Centre also includes a new pilot plant located in a separate building, which carries out the scale-up of active ingredients developed by Egis. In this phase drug development expands from lab-scale glass vessels to pilot-scale, several-hundred-liter reactors in order to work out a technology suitable for industrial-scale production. Besides, scale-up provides the active ingredient demand for the next stages of the development (including finished product formulation tests, as well as biological and toxicological tests and human clinical trials).

• Tags:
• companies,
• api,
• market,
• equity,
• egis